Literature DB >> 35463553

Health technology assessment of varicella vaccine in the Armed Forces.

Seema Patrikar1, V K Bhatti2, Vani Suryam3, A Kotwal4, D R Basannar5, A Khera6, Surekha Kashyap7, Ashutosh Sharma8.   

Abstract

Background: The Indian Armed Forces, on entry, vaccinates all cadets and recruits with varicella vaccine for the prevention of varicella. This health technology assessment (HTA) report puts forth evidence for HTA of varicella vaccination in the Armed Forces in various domains namely clinical, societal, ethical, economic, and legal.
Methods: The policy question under each domain has been developed according to best-practice methods for HTA. The costs included were hospitalization cost due to varicella infection; training lost cost; the varicella vaccine cost; cost of the side effects of vaccine; and the outbreak investigation cost. The incremental cost-effectiveness ratio (ICER) for varicella cases averted and man-days saved, and quality-adjusted life years (QALYs) gained due to varicella vaccination strategy were calculated.
Results: Evidence suggests a reduction of 81% in hospitalization rates with 19392 man-days saved per 1 lakh population due to varicella vaccination strategy. The ICER for varicella cases averted is estimated to be Rs 56732/- per case averted and Rs 5687/- per man-day saved. QALYs gained due to two-dose varicella vaccination strategy is estimated to be 1152 per 1 lakh population with cost per QALY gained Rs 95735/-.
Conclusion: The study showed a large reduction in hospitalizations and consequently man-days lost after the introduction of the vaccination strategy. The QALYs was another aspect of importance brought out by this study. Thus, a two-dose vaccination strategy for varicella-zoster virus (VZV) for the Armed Forces trainees is a cost-effective policy.
© 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Chickenpox; Cost effectiveness; Health technology assessment; Varicella

Year:  2021        PMID: 35463553      PMCID: PMC9023555          DOI: 10.1016/j.mjafi.2021.06.010

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  22 in total

1.  Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.

Authors:  Thomas Hanslik; Pierre-Yves Boëlle; Michael Schwarzinger; Fabrice Carrat; Kenneth A Freedberg; Alain-Jacques Valleron; Antoine Flahault
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

Review 2.  Immunization to protect the US Armed Forces: heritage, current practice, and prospects.

Authors:  John D Grabenstein; Phillip R Pittman; John T Greenwood; Renata J M Engler
Journal:  Epidemiol Rev       Date:  2006-06-08       Impact factor: 6.222

3.  Varicella vaccination in Australia and New Zealand.

Authors:  Kristine K Macartney; Margaret A Burgess
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

4.  Seroepidemiology of varicella.

Authors:  R Muench; C Nassim; S Niku; J Z Sullivan-Bolyai
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

5.  Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain.

Authors:  Manuel García Cenoz; Víctor Martínez-Artola; Marcela Guevara; Carmen Ezpeleta; Aurelio Barricarte; Jesús Castilla
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

6.  Population-based studies of varicella complications.

Authors:  H A Guess; D D Broughton; L J Melton; L T Kurland
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

Review 7.  Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine.

Authors:  P R Krause; D M Klinman
Journal:  J Pediatr       Date:  1995-10       Impact factor: 4.406

8.  Postlicensure safety surveillance for varicella vaccine.

Authors:  R P Wise; M E Salive; M M Braun; G T Mootrey; J F Seward; L G Rider; P R Krause
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 9.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

10.  Controversies in chicken-pox immunization.

Authors:  Swati Y Bhave
Journal:  Indian J Pediatr       Date:  2003-06       Impact factor: 5.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.